KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Divestments (2017 - 2021)

Abbott Laboratories' Divestments history spans 5 years, with the latest figure at $86.0 million for Q3 2021.

  • For Q3 2021, Divestments changed N/A year-over-year to $86.0 million; the TTM value through Dec 2022 reached $86.0 million, down 10.42%, while the annual FY2024 figure was $1.0 million, 97.5% down from the prior year.
  • Divestments for Q3 2021 was $86.0 million at Abbott Laboratories, up from $10.0 million in the prior quarter.
  • Across five years, Divestments topped out at $5.5 billion in Q1 2017 and bottomed at -$29.0 million in Q3 2017.
  • The 3-year median for Divestments is $48.0 million (2020), against an average of $1.0 billion.
  • The largest YoY upside for Divestments was 21788.0% in 2017 against a maximum downside of 21788.0% in 2017.
  • A 3-year view of Divestments shows it stood at $600.0 million in 2017, then plummeted by 98.33% to $10.0 million in 2020, then soared by 760.0% to $86.0 million in 2021.
  • Per Business Quant, the three most recent readings for ABT's Divestments are $86.0 million (Q3 2021), $10.0 million (Q4 2020), and $600.0 million (Q4 2017).